Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B

Publisher： Karger

E-ISSN： 1423-0100|48|6|381-388

ISSN： 0300-5526

Source： Intervirology, Vol.48, Iss.6, 2005-07, pp. : 381-388

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment

By  

Intervirology, Vol. 48, Iss. 2-3, 2005-03 ,pp. : 174-182

Karger

Access to resources Recommend Favorite

Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 867-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Short-Term Lamivudine Therapy in Patients with Chronic Hepatitis B

By  

Intervirology, Vol. 46, Iss. 6, 2003-12 ,pp. : 362-366

Karger

Access to resources Recommend Favorite

Viral Breakthrough during Lamivudine Therapy for Chronic Hepatitis B

By  

Intervirology, Vol. 46, Iss. 6, 2003-12 ,pp. : 344-349

Karger

Access to resources Recommend Favorite

Short-Term Lamivudine for the Treatment of Chronic Hepatitis B

By  

Intervirology, Vol. 46, Iss. 6, 2003-12 ,pp. : 367-372

Karger

Access to resources Recommend Favorite